Privia Health Group (PRVA) Financials

$22.71 -0.35 (-1.51%)

As of 03:47 PM Eastern

Annual Income Statements for Privia Health Group

This table shows Privia Health Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	8.24	31	-188	-8.59	23	14	23
Consolidated Net Income / (Loss)	7.95	31	-191	-12	21	17	30
Net Income / (Loss) Continuing Operations	7.95	31	-191	-12	21	17	30
Total Pre-Tax Income	9.15	23	-219	-19	29	28	44
Total Operating Income	16	25	-217	-19	21	17	34
Total Gross Profit	691	712	791	1,186	1,460	1,509	1,870
Total Revenue	786	817	966	1,357	1,658	1,736	2,123
Operating Revenue	786	817	966	1,357	1,658	1,736	2,123
Total Cost of Revenue	95	105	175	171	198	227	253
Operating Cost of Revenue	95	105	175	171	198	227	253
Total Operating Expenses	675	687	1,009	1,205	1,439	1,492	1,836
Selling, General & Admin Expense	42	44	256	130	110	126	138
Marketing Expense	9.16	11	23	20	25	26	27
Depreciation Expense	1.43	1.84	2.46	4.57	6.53	7.27	9.91
Other Operating Expenses / (Income)	623	629	728	1,051	1,299	1,333	1,661
Total Other Income / (Expense), net	-6.91	-1.92	-1.07	0.54	8.37	11	9.70
Other Income / (Expense), net	-	-	-	0.54	8.37	11	9.70
Income Tax Expense	1.21	-7.44	-28	-6.52	7.99	11	14
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.30	-0.34	-2.42	-3.48	-2.05	2.66	6.81
Basic Earnings per Share	$0.09	$0.33	($1.83)	($0.08)	$0.20	$0.12	$0.19
Weighted Average Basic Shares Outstanding	95.93M	95.95M	102.95M	110.70M	116.73M	119.40M	122.18M
Diluted Earnings per Share	$0.09	$0.33	($1.83)	($0.08)	$0.19	$0.11	$0.18
Weighted Average Diluted Shares Outstanding	95.93M	95.95M	102.95M	110.70M	124.69M	125.61M	128.89M
Weighted Average Basic & Diluted Shares Outstanding	-	-	108.17M	115.00M	118.57M	120.51M	123.69M

This table shows Privia Health Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	5.64	2.84	2.98	3.47	3.54	4.40	4.22	2.69	6.86	9.15	3.06
Consolidated Net Income / (Loss)	5.94	2.32	3.06	4.64	3.98	5.37	6.05	3.29	9.81	11	3.71
Net Income / (Loss) Continuing Operations	5.94	2.32	3.06	4.64	3.98	5.37	6.05	3.29	9.81	11	3.71
Total Pre-Tax Income	8.43	4.27	3.81	8.06	7.98	8.02	8.15	5.74	17	13	9.31
Total Operating Income	5.54	1.42	0.82	5.10	5.81	5.25	5.22	3.34	14	11	7.42
Total Gross Profit	367	388	361	365	382	401	421	456	519	474	535
Total Revenue	417	441	415	422	438	461	480	521	580	541	604
Operating Revenue	417	441	415	422	438	461	480	521	580	541	604
Total Cost of Revenue	50	52	54	57	56	60	60	65	61	67	68
Operating Cost of Revenue	50	52	54	57	56	60	60	65	61	67	68
Total Operating Expenses	361	387	360	360	376	396	415	453	505	463	528
Selling, General & Admin Expense	27	30	32	29	31	34	32	38	40	29	41
Marketing Expense	7.24	6.25	6.09	6.85	7.05	6.46	6.92	6.81	6.96	6.45	8.13
Depreciation Expense	1.73	1.77	1.82	1.82	1.80	1.83	1.90	2.58	2.77	2.66	3.28
Other Operating Expenses / (Income)	325	349	320	323	337	353	375	406	455	425	475
Total Other Income / (Expense), net	2.89	2.85	2.98	2.97	2.16	2.77	2.93	2.41	2.27	2.09	1.89
Other Income / (Expense), net	2.89	-	2.98	2.97	2.16	-	2.93	2.41	2.27	2.09	1.89
Income Tax Expense	2.49	1.94	0.75	3.42	4.00	2.66	2.10	2.46	6.87	2.79	5.60
Net Income / (Loss) Attributable to Noncontrolling Interest	0.30	-0.51	0.07	1.18	0.44	0.97	1.83	0.60	2.95	1.43	0.65
Basic Earnings per Share	$0.05	$0.03	$0.03	$0.03	$0.03	$0.03	$0.03	$0.02	$0.06	$0.08	$0.02
Weighted Average Basic Shares Outstanding	117.60M	116.73M	118.51M	119.30M	119.66M	119.40M	120.62M	122.13M	122.77M	122.18M	124.15M
Diluted Earnings per Share	$0.05	$0.02	$0.02	$0.03	$0.03	$0.03	$0.03	$0.02	$0.05	$0.08	$0.02
Weighted Average Diluted Shares Outstanding	124.92M	124.69M	125.05M	125.32M	125.75M	125.61M	127.75M	128.45M	128.78M	128.89M	130.88M
Weighted Average Basic & Diluted Shares Outstanding	118.06M	118.57M	119.32M	119.56M	120.00M	120.51M	121.92M	122.73M	123.00M	123.69M	126.01M

This table details how cash moves in and out of Privia Health Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	7.78	38	236	27	42	102	-11
Net Cash From Operating Activities	24	39	55	47	81	109	163
Net Cash From Continuing Operating Activities	24	39	55	47	81	109	163
Net Income / (Loss) Continuing Operations	7.95	31	-191	-12	21	17	30
Consolidated Net Income / (Loss)	7.95	31	-191	-12	21	17	30
Depreciation Expense	0.78	1.19	1.15	1.22	1.17	1.10	0.74
Amortization Expense	0.98	0.78	1.47	4.04	5.36	6.16	9.17
Non-Cash Adjustments To Reconcile Net Income	0.21	0.48	267	67	37	57	71
Changes in Operating Assets and Liabilities, net	14	5.54	-24	-13	16	28	53
Net Cash From Investing Activities	-5.71	-0.38	-33	-0.10	-43	-12	-182
Net Cash From Continuing Investing Activities	-5.71	-0.38	-33	-0.10	-43	-12	-182
Acquisitions	0.00	0.00	-32	0.00	-43	-6.96	-180
Other Investing Activities, net	-	-	-	-0.10	-0.11	-5.02	-1.20
Net Cash From Financing Activities	-11	-0.77	214	-20	3.71	4.33	6.70
Net Cash From Continuing Financing Activities	-11	-0.77	214	-20	3.71	4.33	6.70
Payment of Dividends	-	-	0.00	0.00	-5.69	0.00	-1.35
Issuance of Common Equity	0.00	0.00	224	0.13	0.66	1.65	0.00
Other Financing Activities, net	0.00	0.11	3.83	13	8.74	2.68	8.05
Cash Interest Paid	9.20	1.93	0.89	0.71	0.04	0.29	0.25
Cash Income Taxes Paid	0.32	0.38	0.50	0.31	1.04	3.76	6.64

This table details how cash moves in and out of Privia Health Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	12	59	-38	36	35	69	-22	-79	51	38	-60
Net Cash From Operating Activities	22	64	-33	34	33	75	-24	7.97	52	128	-49
Net Cash From Continuing Operating Activities	22	64	-33	34	33	75	-24	7.97	52	128	-49
Net Income / (Loss) Continuing Operations	5.94	2.32	3.06	4.64	3.98	5.37	6.05	3.29	9.81	11	3.71
Consolidated Net Income / (Loss)	5.94	2.32	3.06	4.64	3.98	5.37	6.05	3.29	9.81	11	3.71
Depreciation Expense	0.30	0.30	0.29	0.29	0.29	0.23	0.23	0.19	0.17	0.16	0.15
Amortization Expense	1.43	1.48	1.53	1.53	1.51	1.60	1.67	2.40	2.60	2.50	3.14
Non-Cash Adjustments To Reconcile Net Income	8.29	14	11	14	15	15	18	19	19	15	22
Changes in Operating Assets and Liabilities, net	6.50	46	-49	14	12	52	-50	-17	20	99	-78
Net Cash From Investing Activities	-13	-5.02	-5.71	-	-	-6.27	0.00	-89	-1.20	-91	-0.03
Net Cash From Continuing Investing Activities	-13	-5.02	-5.71	-	-	-6.27	0.00	-89	-1.20	-91	-0.03
Other Investing Activities, net	-0.02	-0.02	-5.01	-	-	-0.02	0.00	-	-1.20	-	-0.03
Net Cash From Financing Activities	3.01	0.04	0.48	1.75	1.49	0.62	2.24	1.88	0.43	2.15	-11
Net Cash From Continuing Financing Activities	3.01	0.04	0.48	1.75	1.49	0.62	2.24	1.88	0.43	2.15	-11
Payment of Dividends	-	-	-	-	-	-	0.00	-	-	-	-11
Other Financing Activities, net	3.01	-0.05	0.48	0.75	0.84	0.62	2.24	1.88	0.43	3.49	0.77
Cash Interest Paid	-0.02	-	0.09	0.06	0.07	0.06	0.00	0.12	0.06	0.06	0.06
Cash Income Taxes Paid	0.42	0.02	-0.23	3.11	0.64	0.23	-0.31	6.08	-	0.87	0.06

This table presents Privia Health Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	329	686	793	1,000	1,136	1,369
Total Current Assets	190	447	552	701	835	911
Cash & Equivalents	85	321	348	390	491	480
Accounts Receivable	99	117	190	291	316	401
Prepaid Expenses	6.33	8.70	14	21	27	30
Plant, Property, & Equipment, net	4.81	4.50	3.39	2.33	1.24	0.50
Total Noncurrent Assets	134	235	237	297	300	458
Goodwill	119	128	127	139	142	210
Intangible Assets	5.98	60	57	108	110	216
Noncurrent Deferred & Refundable Income Taxes	4.95	33	40	35	26	2.27
Other Noncurrent Operating Assets	4.48	14	13	15	22	30
Total Liabilities & Shareholders' Equity	329	686	793	1,000	1,136	1,369
Total Liabilities	185	236	274	393	452	578
Total Current Liabilities	147	190	264	387	449	569
Accounts Payable	39	46	53	58	82	97
Other Current Liabilities	107	144	211	329	367	472
Total Noncurrent Liabilities	38	46	9.49	5.56	3.19	9.92
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	0.00
Other Noncurrent Operating Liabilities	5.60	14	9.49	5.56	3.19	9.92
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	144	450	519	607	683	791
Total Preferred & Common Equity	147	427	499	561	635	737
Total Common Equity	147	427	499	561	635	737
Common Stock	167	635	716	755	814	894
Retained Earnings	-20	-208	-217	-194	-179	-156
Noncontrolling Interest	-3.10	23	20	46	48	54

This table presents Privia Health Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	808	875	938	992	1,032	1,078	1,146	1,184	1,273	1,351	1,418
Total Current Assets	580	589	654	698	728	780	854	886	883	971	966
Cash & Equivalents	317	311	318	330	351	387	422	469	390	441	420
Accounts Receivable	246	261	320	350	346	370	409	389	444	499	514
Prepaid Expenses	16	17	16	17	31	22	23	28	49	31	33
Plant, Property, & Equipment, net	3.66	3.10	2.88	2.60	2.04	1.75	1.46	1.01	0.83	0.66	0.38
Total Noncurrent Assets	224	283	281	292	301	296	290	296	389	379	451
Goodwill	127	135	135	136	139	139	139	142	172	172	210
Intangible Assets	58	98	96	107	106	105	103	108	170	168	213
Noncurrent Deferred & Refundable Income Taxes	27	39	37	35	34	31	28	25	24	17	0.00
Other Noncurrent Operating Assets	12	12	12	14	22	21	20	22	23	23	29
Total Liabilities & Shareholders' Equity	808	875	938	992	1,032	1,078	1,146	1,184	1,273	1,351	1,418
Total Liabilities	317	319	366	401	409	434	483	474	539	588	612
Total Current Liabilities	305	310	358	394	404	430	479	471	535	583	601
Accounts Payable	47	46	49	54	51	61	66	68	74	85	81
Other Current Liabilities	257	263	310	340	353	369	414	403	461	498	521
Total Noncurrent Liabilities	12	9.13	7.82	7.08	4.96	4.42	3.91	3.20	4.14	5.31	11
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	-	-	-	0.25
Other Noncurrent Operating Liabilities	12	9.13	7.82	7.08	4.96	4.42	3.91	3.20	4.14	5.31	10
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	491	557	571	591	623	644	662	710	734	763	806
Total Preferred & Common Equity	470	513	525	545	577	595	615	659	683	709	753
Total Common Equity	470	513	525	545	577	595	615	659	683	709	753
Common Stock	705	723	727	741	767	783	799	834	855	875	906
Retained Earnings	-234	-209	-202	-196	-191	-187	-184	-175	-172	-165	-153
Noncontrolling Interest	21	43	46	46	46	48	47	50	51	54	53

This table displays calculated financial ratios and metrics derived from Privia Health Group's official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	3.91%	18.25%	40.41%	22.19%	4.74%	22.26%
EBITDA Growth	0.00%	53.44%	-885.60%	93.80%	366.88%	-1.17%	53.24%
EBIT Growth	0.00%	58.01%	-956.72%	91.46%	256.19%	-3.97%	57.65%
NOPAT Growth	0.00%	139.74%	-555.31%	91.21%	211.78%	-30.59%	123.02%
Net Income Growth	0.00%	288.97%	-716.91%	93.67%	274.30%	-18.95%	74.41%
EPS Growth	0.00%	266.67%	-654.55%	95.63%	337.50%	-42.11%	63.64%
Operating Cash Flow Growth	0.00%	59.66%	41.57%	-14.28%	71.17%	35.28%	49.53%
Free Cash Flow Firm Growth	0.00%	0.00%	-274.17%	89.95%	-43.02%	212.89%	-366.36%
Invested Capital Growth	0.00%	0.00%	74.98%	5.48%	27.37%	-11.74%	61.86%
Revenue Q/Q Growth	0.00%	0.00%	6.81%	7.03%	4.83%	1.17%	3.93%
EBITDA Q/Q Growth	0.00%	0.00%	-11.90%	62.42%	29.88%	72.57%	12.95%
EBIT Q/Q Growth	0.00%	0.00%	-12.12%	54.37%	35.12%	111.87%	13.86%
NOPAT Q/Q Growth	0.00%	0.00%	-12.12%	53.04%	-44.83%	35.99%	29.30%
Net Income Q/Q Growth	0.00%	0.00%	-8.95%	70.43%	-40.85%	21.73%	21.29%
EPS Q/Q Growth	0.00%	0.00%	-9.58%	78.38%	-44.12%	10.00%	38.46%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-14.02%	724.82%	76.24%	10.85%	47.61%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	82.50%	46.34%	27.91%	-51.31%
Invested Capital Q/Q Growth	0.00%	0.00%	115.01%	-1.79%	-16.41%	-19.94%	-3.16%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	87.89%	87.15%	81.92%	87.41%	88.08%	86.93%	88.09%
EBITDA Margin	2.27%	3.35%	-22.23%	-0.98%	2.14%	2.02%	2.54%
Operating Margin	2.04%	3.11%	-22.50%	-1.41%	1.25%	0.98%	1.61%
EBIT Margin	2.04%	3.11%	-22.50%	-1.37%	1.75%	1.61%	2.07%
Profit (Net Income) Margin	1.01%	3.78%	-19.73%	-0.89%	1.27%	0.98%	1.40%
Tax Burden Percent	86.81%	131.71%	87.25%	64.93%	72.46%	61.16%	67.65%
Interest Burden Percent	56.98%	92.45%	100.49%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	13.19%	-31.71%	0.00%	0.00%	27.54%	38.84%	32.35%
Return on Invested Capital (ROIC)	0.00%	72.14%	-119.45%	-8.03%	7.69%	5.06%	9.20%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	82.05%	-96.77%	-8.45%	6.05%	3.55%	7.85%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-29.11%	55.24%	5.54%	-3.96%	-2.42%	-5.17%
Return on Equity (ROE)	0.00%	43.03%	-64.21%	-2.49%	3.73%	2.64%	4.03%
Cash Return on Invested Capital (CROIC)	0.00%	-127.86%	-173.98%	-13.37%	-16.38%	17.54%	-38.05%
Operating Return on Assets (OROA)	0.00%	7.72%	-42.83%	-2.51%	3.24%	2.61%	3.51%
Return on Assets (ROA)	0.00%	9.39%	-37.55%	-1.63%	2.35%	1.60%	2.37%
Return on Common Equity (ROCE)	0.00%	43.95%	-62.02%	-2.38%	3.52%	2.45%	3.75%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.06%	-44.66%	-2.42%	3.75%	2.68%	0.00%
Net Operating Profit after Tax (NOPAT)	14	33	-152	-13	15	10	23
NOPAT Margin	1.77%	4.09%	-15.75%	-0.99%	0.90%	0.60%	1.09%
Net Nonoperating Expense Percent (NNEP)	0.00%	-9.91%	-22.68%	0.42%	1.65%	1.51%	1.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-2.58%	2.46%	1.52%	2.93%
Cost of Revenue to Revenue	12.11%	12.85%	18.08%	12.59%	11.92%	13.07%	11.91%
SG&A Expenses to Revenue	5.32%	5.39%	26.48%	9.55%	6.61%	7.27%	6.51%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	85.84%	84.04%	104.42%	88.82%	86.83%	85.95%	86.48%
Earnings before Interest and Taxes (EBIT)	16	25	-217	-19	29	28	44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	18	27	-215	-13	36	35	54
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.06	6.45	5.20	4.84	3.69	3.96
Price to Tangible Book Value (P/TBV)	0.00	20.29	11.52	8.25	8.63	6.11	9.36
Price to Revenue (P/Rev)	0.57	0.55	2.85	1.91	1.64	1.35	1.37
Price to Earnings (P/E)	54.40	14.35	0.00	0.00	117.81	163.09	127.25
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.84%	6.97%	0.00%	0.00%	0.85%	0.61%	0.79%
Enterprise Value to Invested Capital (EV/IC)	0.00	4.26	15.36	13.26	10.90	9.90	8.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.48	2.58	1.67	1.43	1.10	1.17
Enterprise Value to EBITDA (EV/EBITDA)	0.00	14.42	0.00	0.00	66.81	54.16	46.25
Enterprise Value to EBIT (EV/EBIT)	0.00	15.54	0.00	0.00	81.85	68.29	56.68
Enterprise Value to NOPAT (EV/NOPAT)	0.00	11.80	0.00	0.00	158.77	183.25	107.52
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	10.14	45.23	48.05	29.40	17.42	15.24
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	52.92	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.23	0.07	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.23	0.07	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.35	-0.57	-0.66	-0.65	-0.68	-0.66
Leverage Ratio	0.00	2.29	1.71	1.53	1.59	1.65	1.70
Compound Leverage Factor	0.00	2.12	1.72	1.53	1.59	1.65	1.70
Debt to Total Capital	0.00%	18.98%	6.75%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.49%	0.18%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	18.49%	6.56%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-1.75%	4.83%	3.84%	7.57%	7.06%	6.79%
Common Equity to Total Capital	0.00%	82.76%	88.43%	96.16%	92.43%	92.94%	93.21%
Debt to EBITDA	0.00	1.23	-0.15	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	-1.86	1.34	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	1.20	-0.15	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	1.01	-0.21	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	-1.52	1.89	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.98	-0.21	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	4.26	7.38	7.38	6.02	4.91	4.82
Noncontrolling Interest Sharing Ratio	0.00%	-2.16%	3.40%	4.46%	5.85%	7.30%	6.92%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	1.29	2.35	2.09	1.81	1.86	1.60
Quick Ratio	0.00	1.25	2.30	2.03	1.76	1.80	1.55
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-59	-222	-22	-32	36	-96
Operating Cash Flow to CapEx	426.66%	10,234.47%	10,065.45%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-30.91	-207.19	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	3.53	20.29	51.46	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	2.70	20.09	50.94	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	2.48	1.90	1.83	1.85	1.63	1.69
Accounts Receivable Turnover	0.00	8.24	8.93	8.84	6.90	5.72	5.92
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	169.73	207.43	343.98	580.54	973.59	2,431.66
Accounts Payable Turnover	0.00	2.68	4.10	3.46	3.57	3.25	2.83
Days Sales Outstanding (DSO)	0.00	44.28	40.90	41.30	52.88	63.79	61.65
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	136.44	89.03	105.57	102.18	112.41	129.11
Cash Conversion Cycle (CCC)	0.00	-92.16	-48.13	-64.27	-49.29	-48.62	-67.46
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	93	162	171	218	192	311
Invested Capital Turnover	0.00	17.63	7.58	8.14	8.52	8.47	8.43
Increase / (Decrease) in Invested Capital	0.00	93	69	8.89	47	-26	119
Enterprise Value (EV)	0.00	394	2,490	2,268	2,375	1,903	2,490
Market Capitalization	449	449	2,755	2,596	2,719	2,346	2,916
Book Value per Share	$0.00	$1.53	$4.01	$4.37	$4.76	$5.29	$5.99
Tangible Book Value per Share	$0.00	$0.23	$2.25	$2.75	$2.67	$3.20	$2.53
Total Capital	0.00	177	483	519	607	683	791
Total Debt	0.00	34	33	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	33	32	0.00	0.00	0.00	0.00
Net Debt	0.00	-51	-288	-348	-390	-491	-480
Capital Expenditures (CapEx)	5.71	0.38	0.55	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-41	-63	-60	-76	-105	-137
Debt-free Net Working Capital (DFNWC)	0.00	44	257	288	314	386	342
Net Working Capital (NWC)	0.00	43	256	288	314	386	342
Net Nonoperating Expense (NNE)	6.00	2.52	38	-1.32	-6.07	-6.66	-6.56
Net Nonoperating Obligations (NNO)	0.00	-51	-288	-348	-390	-491	-480
Total Depreciation and Amortization (D&A)	1.76	1.96	2.62	5.26	6.53	7.27	9.91
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-4.97%	-6.57%	-4.45%	-4.56%	-6.07%	-6.46%
Debt-free Net Working Capital to Revenue	0.00%	5.39%	26.61%	21.21%	18.93%	22.21%	16.13%
Net Working Capital to Revenue	0.00%	5.28%	26.52%	21.21%	18.93%	22.21%	16.13%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($1.83)	($0.08)	$0.20	$0.12	$0.19
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	102.95M	110.70M	116.73M	119.40M	122.18M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($1.83)	($0.08)	$0.19	$0.11	$0.18
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	102.95M	110.70M	124.69M	125.61M	128.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	108.17M	115.00M	118.57M	120.51M	123.69M
Normalized Net Operating Profit after Tax (NOPAT)	14	18	-152	-13	15	10	23
Normalized NOPAT Margin	1.77%	2.17%	-15.75%	-0.99%	0.90%	0.60%	1.09%
Pre Tax Income Margin	1.16%	2.87%	-22.61%	-1.37%	1.75%	1.61%	2.07%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	2.32	13.24	-203.21	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	2.02	17.44	-142.25	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	1.50	13.04	-203.72	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	1.19	17.24	-142.76	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	27.08%	0.00%	4.52%
Augmented Payout Ratio	0.00%	0.00%	-6.66%	0.00%	27.08%	0.00%	4.52%

This table displays calculated financial ratios and metrics derived from Privia Health Group's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	123,688,289.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	123,688,289.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.02
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.69%	20.97%	7.50%	2.17%	4.95%	4.55%	15.62%	23.40%	32.54%	17.42%	25.78%
EBITDA Growth	397.02%	-5.67%	-67.17%	4.17%	-3.81%	121.80%	78.57%	-15.74%	98.90%	62.65%	25.28%
EBIT Growth	284.30%	-36.86%	-87.74%	3.44%	-5.37%	269.58%	114.05%	-28.77%	109.03%	66.68%	14.25%
NOPAT Growth	221.87%	-93.06%	-86.89%	-48.45%	-25.71%	354.09%	486.00%	-34.94%	192.23%	154.28%	-23.60%
Net Income Growth	968.71%	-86.21%	-52.26%	-27.00%	-33.05%	130.94%	97.84%	-29.18%	146.53%	97.22%	-38.64%
EPS Growth	400.00%	-88.24%	-66.67%	-50.00%	-40.00%	50.00%	50.00%	-33.33%	66.67%	166.67%	-33.33%
Operating Cash Flow Growth	39.12%	119.87%	-147.59%	353.10%	47.61%	16.69%	27.39%	-76.87%	56.83%	70.46%	-105.58%
Free Cash Flow Firm Growth	18.99%	-2,145.50%	60.95%	100.06%	128.31%	163.18%	237.42%	-192,680.00%	-411.18%	-478.23%	-505.00%
Invested Capital Growth	49.66%	27.37%	10.76%	1.14%	-7.86%	-11.74%	-11.59%	34.01%	33.82%	61.86%	60.86%
Revenue Q/Q Growth	0.95%	5.64%	-5.80%	1.71%	3.69%	5.25%	4.17%	8.55%	11.37%	-6.76%	11.58%
EBITDA Q/Q Growth	7.12%	-68.59%	-17.17%	273.75%	-1.09%	-27.56%	41.95%	-17.14%	133.46%	-17.55%	-21.44%
EBIT Q/Q Growth	8.13%	-83.16%	-42.04%	879.83%	-1.08%	-34.21%	55.28%	-29.51%	190.29%	-19.81%	-30.37%
NOPAT Q/Q Growth	-31.46%	-80.18%	-14.56%	344.30%	-1.24%	21.12%	10.26%	-50.67%	343.61%	5.39%	-66.87%
Net Income Q/Q Growth	-6.57%	-60.89%	31.50%	51.93%	-14.32%	34.92%	12.65%	-45.62%	198.27%	7.93%	-64.95%
EPS Q/Q Growth	-16.67%	-60.00%	0.00%	50.00%	0.00%	0.00%	0.00%	-33.33%	150.00%	60.00%	-75.00%
Operating Cash Flow Q/Q Growth	195.27%	185.39%	-151.70%	204.01%	-3.81%	125.61%	-132.17%	133.13%	552.29%	145.22%	-138.80%
Free Cash Flow Firm Q/Q Growth	-13.52%	44.25%	44.11%	100.17%	52,712.42%	24.43%	21.56%	-341.07%	14.66%	-51.24%	-30.17%
Invested Capital Q/Q Growth	2.88%	-16.41%	24.70%	-5.68%	-6.27%	-19.94%	24.91%	42.98%	-6.41%	-3.16%	24.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.94%	88.11%	86.98%	86.48%	87.20%	87.03%	87.60%	87.54%	89.41%	87.65%	88.67%
EBITDA Margin	2.44%	0.72%	0.64%	2.34%	2.23%	1.54%	2.09%	1.60%	3.35%	2.96%	2.09%
Operating Margin	1.33%	0.32%	0.20%	1.21%	1.33%	1.14%	1.09%	0.64%	2.48%	2.08%	1.23%
EBIT Margin	2.02%	0.32%	0.20%	1.91%	1.82%	1.14%	1.70%	1.10%	2.87%	2.47%	1.54%
Profit (Net Income) Margin	1.42%	0.53%	0.74%	1.10%	0.91%	1.16%	1.26%	0.63%	1.69%	1.96%	0.61%
Tax Burden Percent	70.49%	54.45%	80.27%	57.58%	49.87%	66.90%	74.19%	57.24%	58.82%	79.16%	39.85%
Interest Burden Percent	100.00%	300.56%	462.58%	100.00%	100.00%	152.86%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	29.51%	45.55%	19.73%	42.42%	50.13%	33.10%	25.81%	42.76%	41.18%	20.84%	60.15%
Return on Invested Capital (ROIC)	6.80%	1.50%	1.04%	4.63%	4.54%	6.45%	5.68%	2.32%	10.62%	13.91%	3.51%
ROIC Less NNEP Spread (ROIC-NNEP)	6.17%	1.07%	0.31%	4.14%	4.25%	6.03%	5.15%	1.97%	10.31%	13.57%	3.34%
Return on Net Nonoperating Assets (RNNOA)	-3.69%	-0.70%	-0.18%	-2.40%	-2.55%	-4.11%	-3.17%	-1.11%	-6.25%	-8.93%	-1.96%
Return on Equity (ROE)	3.11%	0.79%	0.86%	2.22%	1.99%	2.34%	2.51%	1.21%	4.37%	4.98%	1.55%
Cash Return on Invested Capital (CROIC)	-27.31%	-16.38%	-6.06%	2.15%	11.23%	17.54%	17.50%	-24.98%	-22.55%	-38.05%	-39.60%
Operating Return on Assets (OROA)	3.55%	0.60%	0.35%	3.21%	2.92%	1.85%	2.76%	1.78%	4.70%	4.19%	2.66%
Return on Assets (ROA)	2.50%	0.98%	1.30%	1.85%	1.46%	1.89%	2.05%	1.02%	2.76%	3.31%	1.06%
Return on Common Equity (ROCE)	2.92%	0.75%	0.80%	2.05%	1.84%	2.17%	2.33%	1.12%	4.06%	4.63%	1.45%
Return on Equity Simple (ROE_SIMPLE)	6.53%	0.00%	3.07%	2.68%	2.28%	0.00%	3.04%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	3.90	0.77	0.66	2.94	2.90	3.51	3.87	1.91	8.47	8.93	2.96
NOPAT Margin	0.94%	0.18%	0.16%	0.70%	0.66%	0.76%	0.81%	0.37%	1.46%	1.65%	0.49%
Net Nonoperating Expense Percent (NNEP)	0.63%	0.42%	0.72%	0.48%	0.29%	0.42%	0.53%	0.35%	0.31%	0.34%	0.17%
Return On Investment Capital (ROIC_SIMPLE)	-	0.13%	-	-	-	0.51%	0.55%	0.26%	1.11%	1.13%	0.37%
Cost of Revenue to Revenue	12.06%	11.89%	13.02%	13.52%	12.80%	12.97%	12.40%	12.46%	10.59%	12.35%	11.33%
SG&A Expenses to Revenue	6.53%	6.71%	7.74%	6.85%	7.01%	7.47%	6.61%	7.20%	6.83%	5.41%	6.87%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	86.61%	87.79%	86.78%	85.27%	85.87%	85.89%	86.51%	86.90%	86.93%	85.56%	87.44%
Earnings before Interest and Taxes (EBIT)	8.43	1.42	0.82	8.06	7.98	5.25	8.15	5.74	17	13	9.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	10	3.19	2.64	9.88	9.77	7.08	10	8.33	19	16	13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.96	4.84	4.01	3.48	3.54	3.69	4.10	4.11	4.31	3.96	3.38
Price to Tangible Book Value (P/TBV)	8.94	8.63	6.98	5.90	5.85	6.11	6.60	8.24	8.27	9.36	7.70
Price to Revenue (P/Rev)	1.71	1.64	1.37	1.22	1.27	1.35	1.50	1.48	1.50	1.37	1.13
Price to Earnings (P/E)	71.00	117.81	123.43	138.88	169.78	163.09	173.20	188.95	168.22	127.25	116.91
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.41%	0.85%	0.81%	0.72%	0.59%	0.61%	0.58%	0.53%	0.59%	0.79%	0.86%
Enterprise Value to Invested Capital (EV/IC)	9.27	10.90	7.39	6.77	7.51	9.90	9.52	7.18	8.30	8.00	5.64
Enterprise Value to Revenue (EV/Rev)	1.53	1.43	1.19	1.02	1.05	1.10	1.27	1.30	1.31	1.17	0.97
Enterprise Value to EBITDA (EV/EBITDA)	88.23	66.81	92.22	86.65	88.53	54.16	57.79	64.85	55.97	46.25	38.62
Enterprise Value to EBIT (EV/EBIT)	112.46	81.85	136.05	134.70	137.04	68.29	70.98	82.45	69.15	56.68	48.28
Enterprise Value to NOPAT (EV/NOPAT)	89.06	158.77	186.97	207.30	236.04	183.25	171.96	201.08	148.96	107.52	98.40
Enterprise Value to Operating Cash Flow (EV/OCF)	52.69	29.40	32.90	19.74	18.28	17.42	19.32	26.83	24.10	15.24	15.78
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	316.73	64.11	52.92	51.05	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.60	-0.65	-0.56	-0.58	-0.60	-0.68	-0.62	-0.56	-0.61	-0.66	-0.59
Leverage Ratio	1.66	1.59	1.62	1.66	1.71	1.65	1.66	1.71	1.75	1.70	1.72
Compound Leverage Factor	1.66	4.78	7.48	1.66	1.71	2.53	1.66	1.71	1.75	1.70	1.72
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	7.85%	7.57%	7.39%	7.49%	7.14%	7.06%	7.06%	6.91%	7.03%	6.79%	6.56%
Common Equity to Total Capital	92.15%	92.43%	92.61%	92.51%	92.86%	92.94%	92.94%	93.09%	92.97%	93.21%	93.44%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.75	5.92	5.15	4.61	4.39	4.84	5.18	4.77	4.84	4.75	4.26
Noncontrolling Interest Sharing Ratio	6.22%	5.85%	7.57%	7.76%	7.47%	7.30%	7.21%	7.18%	7.08%	6.92%	6.79%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.77	1.81	1.80	1.81	1.78	1.86	1.88	1.65	1.67	1.60	1.61
Quick Ratio	1.73	1.76	1.73	1.76	1.73	1.80	1.82	1.56	1.61	1.55	1.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-83	-46	-26	0.04	23	29	35	-85	-73	-110	-143
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.76	1.85	1.77	1.68	1.61	1.63	1.63	1.62	1.64	1.69	1.73
Accounts Receivable Turnover	5.30	6.90	5.56	4.92	4.52	5.72	4.90	4.67	4.50	5.92	4.98
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	505.22	580.54	657.20	733.58	846.94	973.59	1,180.37	1,476.36	1,928.77	2,431.66	3,214.01
Accounts Payable Turnover	3.71	3.57	4.27	3.90	3.66	3.25	3.91	3.56	3.27	2.83	3.52
Days Sales Outstanding (DSO)	68.84	52.88	65.67	74.25	80.71	63.79	74.45	78.19	81.13	61.65	73.31
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	98.30	102.18	85.48	93.59	99.68	112.41	93.25	102.63	111.67	129.11	103.72
Cash Conversion Cycle (CCC)	-29.46	-49.29	-19.81	-19.34	-18.97	-48.62	-18.80	-24.44	-30.54	-67.46	-30.42
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	261	218	272	256	240	192	240	343	321	311	386
Invested Capital Turnover	7.27	8.52	6.53	6.65	6.85	8.47	7.04	6.34	7.27	8.43	7.17
Increase / (Decrease) in Invested Capital	86	47	26	2.89	-20	-26	-31	87	81	119	146
Enterprise Value (EV)	2,415	2,375	2,008	1,735	1,803	1,903	2,286	2,465	2,668	2,490	2,178
Market Capitalization	2,699	2,719	2,313	2,074	2,177	2,346	2,706	2,804	3,056	2,916	2,544
Book Value per Share	$4.64	$4.76	$4.87	$4.99	$5.14	$5.29	$5.47	$5.60	$5.78	$5.99	$6.09
Tangible Book Value per Share	$2.57	$2.67	$2.80	$2.94	$3.11	$3.20	$3.40	$2.79	$3.01	$2.53	$2.67
Total Capital	591	607	623	644	662	683	710	734	763	791	806
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-330	-390	-351	-387	-422	-491	-469	-390	-441	-480	-420
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-27	-76	-27	-37	-48	-105	-54	-42	-53	-137	-55
Debt-free Net Working Capital (DFNWC)	303	314	324	350	374	386	416	348	388	342	365
Net Working Capital (NWC)	303	314	324	350	374	386	416	348	388	342	365
Net Nonoperating Expense (NNE)	-2.04	-1.55	-2.40	-1.71	-1.08	-1.86	-2.17	-1.38	-1.34	-1.66	-0.75
Net Nonoperating Obligations (NNO)	-330	-390	-351	-387	-422	-491	-469	-390	-441	-480	-420
Total Depreciation and Amortization (D&A)	1.73	1.77	1.82	1.82	1.80	1.83	1.90	2.58	2.77	2.66	3.28
Debt-free, Cash-free Net Working Capital to Revenue	-1.70%	-4.56%	-1.59%	-2.20%	-2.78%	-6.07%	-2.98%	-2.21%	-2.61%	-6.46%	-2.44%
Debt-free Net Working Capital to Revenue	19.19%	18.93%	19.23%	20.65%	21.81%	22.21%	23.08%	18.32%	19.00%	16.13%	16.23%
Net Working Capital to Revenue	19.19%	18.93%	19.23%	20.65%	21.81%	22.21%	23.08%	18.32%	19.00%	16.13%	16.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.05	$0.03	$0.03	$0.03	$0.03	$0.03	$0.03	$0.02	$0.06	$0.08	$0.02
Adjusted Weighted Average Basic Shares Outstanding	117.60M	116.73M	118.51M	119.30M	119.66M	119.40M	120.62M	122.13M	122.77M	122.18M	124.15M
Adjusted Diluted Earnings per Share	$0.05	$0.02	$0.02	$0.03	$0.03	$0.03	$0.03	$0.02	$0.05	$0.08	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	124.92M	124.69M	125.05M	125.32M	125.75M	125.61M	127.75M	128.45M	128.78M	128.89M	130.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	118.06M	118.57M	119.32M	119.56M	120.00M	120.51M	121.92M	122.73M	123.00M	123.69M	126.01M
Normalized Net Operating Profit after Tax (NOPAT)	3.90	0.77	0.66	2.94	4.07	3.51	3.87	1.91	8.47	8.93	5.20
Normalized NOPAT Margin	0.94%	0.18%	0.16%	0.70%	0.93%	0.76%	0.81%	0.37%	1.46%	1.65%	0.86%
Pre Tax Income Margin	2.02%	0.97%	0.92%	1.91%	1.82%	1.74%	1.70%	1.10%	2.87%	2.47%	1.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	16.02%	27.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.52%	46.69%
Augmented Payout Ratio	16.02%	27.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.52%	46.69%

Financials Breakdown Chart

Key Financial Trends

Privia Health Group (PRVA) has shown solid top-line growth in 2025 across all four quarters, along with strong gross margins and improving cash flow. However, profitability in the latest quarter and acqusition-driven investing weigh on near-term results. Below is a concise, data-driven read on trends from the last four years of quarterly statements.

Revenue growth: 2025 quarters show year-over-year increases across the board, with Q4 2025 revenue of 541.17 million vs 460.93 million in Q4 2024, and similarly higher in Q3 and Q2 relative to the prior-year periods.
High gross margins: 2025 quarters maintained very strong gross margins, e.g., Q4 2025 gross profit of 474.33 million on 541.17 million revenue (about 87.6%), and Q3 2025 gross margin near 89%.
Operating cash flow strengthening: 2025 saw meaningful CFO improvement, with Q4 2025 net cash from continuing operating activities of 127.5 million and Q3 2025 at about 52.0 million, after a weaker start in Q1–Q2.
Low leverage: Long-term debt is effectively zero in the 2025 period, indicating a conservative balance sheet not burdened by debt financing.
Earnings per share uptick: Q4 2025 basic and diluted EPS are 0.08, up from 0.06 in Q4 2024, supported by stronger revenue and margins.
Overall cash-generation trend supports expansion: 2025 CFOs exceeded major investing outflows in late-year quarters (for example, -91.31 million Acquisitions in Q4 2025), suggesting core operating cash flow remains robust.
Accounts receivable levels elevated: AR figures are sizable (e.g., around 499 million in Q3 2025), indicating working capital needs and potential timing effects on cash cycles.
Liquidity range stable: Cash & equivalents hover in the 440–470 million range across 2025 quarters, providing a solid liquidity cushion but also reflecting ongoing working-capital requirements.
Profitability in Q4 2025 challenges prior-year pace: Net income from continuing operations in Q4 2025 was 10.59 million, down from 22.34 million in Q4 2024, signaling margin compression in the latest quarter.
Investing and non-core costs weigh on pretax income: Q4 2025 included substantial Other Operating Expenses (about 424.67 million) and sizable acquisitions cash outflow (approximately 91.31 million), which pressured profitability despite strong revenue.

05/11/26 03:48 PM ETAI Generated. May Contain Errors.

Privia Health Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Privia Health Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Privia Health Group's net income appears to be on a downward trend, with a most recent value of $29.73 million in 2025, rising from $7.95 million in 2019. The previous period was $17.04 million in 2024. Find out what analysts predict for Privia Health Group in the coming months.

Privia Health Group's total operating income in 2025 was $34.24 million, based on the following breakdown:

Total Gross Profit: $1.87 billion
Total Operating Expenses: $1.84 billion

Over the last 6 years, Privia Health Group's total revenue changed from $786.36 million in 2019 to $2.12 billion in 2025, a change of 170.0%.

Privia Health Group's total liabilities were at $578.44 million at the end of 2025, a 27.9% increase from 2024, and a 212.1% increase since 2020.

In the past 5 years, Privia Health Group's cash and equivalents has ranged from $84.63 million in 2020 to $491.15 million in 2024, and is currently $479.69 million as of their latest financial filing in 2025.

Over the last 6 years, Privia Health Group's book value per share changed from 0.00 in 2019 to 5.99 in 2025, a change of 599.4%.

Related Companies

Financial statements for NASDAQ:PRVA last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Privia Health Group (PRVA) Financials

Financials Breakdown Chart

Key Financial Trends

Privia Health Group Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Privia Health Group (PRVA) Financials

Annual Income Statements for Privia Health Group

Quarterly Income Statements for Privia Health Group

Annual Cash Flow Statements for Privia Health Group

Quarterly Cash Flow Statements for Privia Health Group

Annual Balance Sheets for Privia Health Group

Quarterly Balance Sheets for Privia Health Group

Annual Metrics And Ratios for Privia Health Group

Quarterly Metrics And Ratios for Privia Health Group

Financials Breakdown Chart

Key Financial Trends

Privia Health Group Financials - Frequently Asked Questions

When does Privia Health Group's financial year end?

How has Privia Health Group's net income changed over the last 6 years?

What is Privia Health Group's operating income?

How has Privia Health Group's revenue changed over the last 6 years?

How much debt does Privia Health Group have?

How much cash does Privia Health Group have?

How has Privia Health Group's book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools